Specific PI3K isoform modulation in heart failure: Lessons from transgenic mice

Current Heart Failure Reports

Volumn 8, Issue 3, 2011, Pages 168-175

  Ghigo, Alessandra ^a   Morello, Fulvio ^a   Perino, Alessia ^a   Damilano, Federico ^a   Hirsch, Emilio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

adrenergic receptors; Cardiac pathophysiology; Contractility; Heart failure; Hypertrophy; Inflammation; Myocardial infarction; Phosphoinositide 3 kinase; PI3K; PI3K isoform; PI3K ; PI3K ; PIP 3

Indexed keywords

5 (6 QUINOXALINYLMETHYLENE) 2,4 THIAZOLIDINEDIONE; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLIC AMP; CYTOKINE ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1 ANTIBODY; MUTANT PROTEIN; PHOSPHATE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE BETA; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL(3,4,5)TRIPHOSPHATE; PHOSPHODIESTERASE 3B; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PROPRANOLOL; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ADRENERGIC ACTIVITY; ARTICLE; ATHEROSCLEROTIC PLAQUE; BIOSYNTHESIS; CARDIOVASCULAR INFLAMMATION; CELL LEVEL; CELL METABOLISM; DISEASE MODEL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GENE MUTATION; GENE OVEREXPRESSION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HUMAN; INTRACELLULAR SIGNALING; METABOLIC REGULATION; MOLECULAR PATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; TRANSGENIC MOUSE;

ANIMALS; CELL SURVIVAL; DISEASE MODELS, ANIMAL; HEART FAILURE; INFLAMMATION; MICE; MICE, TRANSGENIC; MYOCARDIAL CONTRACTION; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTORS, ADRENERGIC, BETA; SECOND MESSENGER SYSTEMS; SIGNAL TRANSDUCTION;

EID: 80055062907     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-011-0059-3     Document Type: Article

References (64)

1. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296:1655-1657. (Pubitemid 34579158)
2. Hirsch E, Braccini L, Ciraolo E, et al. Twice upon a time: PI3K's secret double life exposed. Trends Biochem Sci (2009); 34:244-248.
3. Vanhaesebroeck B, Ali K, Bilancio A, et al. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci. 2005;30:194-204. (Pubitemid 40463309)
4. Williams R, Berndt A, Miller S, et al. Form and flexibility in phosphoinositide 3-kinases. Biochem Soc Trans. 2009;37:615-626.
5. Ciraolo E, Iezzi M, Marone R, et al. Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development. Sci Signal. 2008;1:ra3.
6. Guillermet-Guibert J, Bjorklof K, Salpekar A, et al. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci USA. 2008;105:8292-8297. (Pubitemid 351904749)
7. Pacold ME, Suire S, Perisic O, et al. Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell. 2000;103:931-943.
8. Franke TF. Intracellular signaling by Akt: bound to be specific. Sci Signal. 2008;1:pe29.
9. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell. 2000;100:387-390.
10. Parsons R, Simpson L. PTEN and cancer. Meth Mol Biol. 2003;222:147-166.
11. Schurmans S, Carrio R, Behrends J, et al. The mouse SHIP2 (Inpp l1) gene: complementary DNA, genomic structure, promoter analysis, and gene expression in the embryo and adult mouse. Genomics. 1999;62:260-271. (Pubitemid 30053942)
12. Lu Z, Jiang YP, Wang W, et al. Loss of cardiac phosphoinositide 3-kinase p110 alpha results in contractile dysfunction. Circulation (2009); 120:318-325.
13. McMullen JR, Shioi T, Huang WY, et al. The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway. J Biol Chem. 2004;279:4782-4793. (Pubitemid 38199073)
14. Bi L, Okabe I, Bernard DJ, et al. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J Biol Chem. 1999;274:10963-10968.
15. Crackower MA, Oudit GY, Kozieradzki I, et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell. 2002;110:737-749. (Pubitemid 35283963)
16. Shioi T, Kang PM, Douglas PS, et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 2000;19:2537-2548. (Pubitemid 30323543)
17. Yano N, Tseng A, Zhao TC, et al. Temporally controlled overexpression of cardiac-specific PI3Kalpha induces enhanced myocardial contractility-a new transgenic model. Am J Physiol Heart Circ Physiol. 2008;295:H1690-1694.
18. Condorelli G, Drusco A, Stassi G, et al. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci USA. 2002;99:12333-12338.
19. DeBosch B, Treskov I, Lupu TS, et al. Akt1 is required for physiological cardiac growth. Circulation. 2006;113:2097-2104.
20. Matsui T, Li L, Wu JC, et al. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem. 2002;277:22896-22901. (Pubitemid 34967272)
21. McMullen JR, Shioi T, Zhang L, et al. Phosphoinositide 3-kinase (p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci USA. 2003;100:12355-12360. (Pubitemid 37271564)
22. Lin RC, Weeks KL, Gao XM, et al. PI3K(p110 alpha) protects against myocardial infarction-induced heart failure: identification of PI3K-regulated miRNA and mRNA. Arterioscler Thromb Vasc Biol (2010); 30:724-732.
23. McMullen JR, Amirahmadi F, Woodcock EA, et al. Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc Natl Acad Sci USA. 2007;104:612-617. (Pubitemid 46123073)
24. Liang W, Oudit GY, Patel MM, et al. Role of phosphoinositide 3- kinase {alpha}, protein kinase C, and L-type Ca2+ channels in mediating the complex actions of angiotensin II on mouse cardiac contractility. Hypertension. 2010;56:422-429.
25. Sun H, Kerfant BG, Zhao D, et al. Insulin-like growth factor-1 and PTEN deletion enhance cardiac L-type Ca2+ currents via increased PI3Kalpha/PKB signaling. Circ Res. 2006;98:1390-1397. (Pubitemid 43948063)
26. Hirsch E, Katanaev VL, Garlanda C, et al. Central role for G proteincoupled phosphoinositide 3-kinase gamma in inflammation. Science. 2000;287:1049-1053.
27. Li Z, Jiang H, Xie W, et al. Roles of PLC-beta2 and -beta3 and PI3Kgamma in chemoattractant-mediated signal transduction. Science. 2000;287:1046-1049. (Pubitemid 30094361)
28. Sasaki T, Irie-Sasaki J, Jones RG, et al. Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science. 2000;287:1040-1046.
29. Laffargue M, Calvez R, Finan P, et al. Phosphoinositide 3-kinase gamma is an essential amplifier of mast cell function. Immunity. 2002;16:441-451. (Pubitemid 34260921)
30. Nombela-Arrieta C, Lacalle RA, Montoya MC, et al. Differential requirements for DOCK2 and phosphoinositide-3-kinase gamma during T and B lymphocyte homing. Immunity. 2004;21:429-441. (Pubitemid 39208343)
31. Shi J, Cinek T, Truitt KE, Imboden JB. Wortmannin, a phosphatidylinositol 3-kinase inhibitor, blocks antigen-mediated, but not CD3 monoclonal antibody-induced, activation of murine CD4+ T cells. J Immunol. 1997;158:4688-4695. (Pubitemid 127483787)
32. Puri KD, Doggett TA, Huang CY, et al. The role of endothelial PI3Kgamma activity in neutrophil trafficking. Blood. 2005; 106:150-157. (Pubitemid 40967187)
33. Vecchione C, Patrucco E, Marino G, et al. Protection from angiotensin II-mediated vasculotoxic to hypertensive response in mice lacking PI3Kgamma. J Exp Med. 2005;201:1217-1228. (Pubitemid 40629066)
34. Chang JD, Sukhova GK, Libby P, et al. Deletion of the phosphoinositide 3-kinase p110gamma gene attenuates murine atherosclerosis. Proc Natl Acad Sci USA. 2007;104:8077-8082. (Pubitemid 47185878)
35. Fougerat A, Gayral S, Gourdy P, et al. Genetic and pharmacological targeting of phosphoinositide 3-kinase-gamma reduces atherosclerosis and favors plaque stability by modulating inflammatory processes. Circulation (2008); 117:1310-1317. (Pubitemid 351365672)
36. Kuwahara F, Kai H, Tokuda K, et al. Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension. 2004;43:739-745. (Pubitemid 38405580)
37. Damilano F, Franco I, Perrino C, et al. Distinct effects of leukocyte and cardiac phosphoinositide 3-kinase gamma activity in pressure overload-induced cardiac failure. Circulation (2011); 123:391-399.
38. Bers DM. Cardiac excitation-contraction coupling. Nature. 2002;415:198-205. (Pubitemid 34059525)
39. Jurevicius J, Skeberdis VA, Fischmeister R. Role of cyclic nucleotide phosphodiesterase isoforms in cAMP compartmentation following beta2-adrenergic stimulation of ICa, L in frog ventricular myocytes. J Physiol. 2003;551:239-252. (Pubitemid 37062925)
40. Zaccolo M, Pozzan T. Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science. 2002;295:1711-1715. (Pubitemid 34202906)
41. Scott JD, Pawson T. Cell signaling in space and time: where proteins come together and when they're apart. Science. 2009;326:1220-1224.
42. Patrucco E, Notte A, Barberis L, et al. PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinasedependent and -independent effects. Cell. 2004;118:375-387. (Pubitemid 39061117)
43. Perino A, Ghigo A, Ferrero E, et al. Integrating cardiac PIP3 and cAMP signaling through a PKA anchoring function of p110γ. Mol Cell (2011); 42:1-12.
44. Haubner BJ, Neely GG, Voelkl JG, et al. PI3Kgamma protects from myocardial ischemia to reperfusion injury through a kinaseindependent pathway. PLoS ONE. 2010;5:e9350.
45. Kerfant BG, Zhao D, Lorenzen-Schmidt I, et al. PI3Kgamma is required for PDE4, not PDE3, activity in subcellular microdomains containing the sarcoplasmic reticular calcium ATPase in cardiomyocytes. Circ Res. 2007;101:400-408. (Pubitemid 47267708)
46. Kerfant BG, Gidrewicz D, Sun H, et al. Cardiac sarcoplasmic reticulum calcium release and load are enhanced by subcellular cAMP elevations in PI3Kgamma-deficient mice. Circ Res. 2005;96:1079-1086. (Pubitemid 40791380)
47. Guo D, Kassiri Z, Basu R, et al. Loss of PI3Kgamma enhances cAMP-dependent MMP remodeling of the myocardial N-cadherin adhesion complexes and extracellular matrix in response to early biomechanical stress. Circ Res. 2010;107:1275-1289.
48. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembranespanning receptors and heart function. Nature. 2002;415:206-212.
49. Bristow MR. Why does the myocardium fail? Insights from basic science. Lancet. 1998;352 Suppl 1:SI8-SI14. (Pubitemid 28398686)
50. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982;307:205-211. (Pubitemid 12079105)
51. Lefkowitz RJ, Whalen EJ. Beta-arrestins: traffic cops of cell signaling. Curr Opin Cell Biol. 2004;16:162-168. (Pubitemid 38757292)
52. Naga Prasad SV, Barak LS, Rapacciuolo A, et al. Agonistdependent recruitment of phosphoinositide 3-kinase to the membrane by beta-adrenergic receptor kinase 1. A role in receptor sequestration. J Biol Chem. 2001;276:18953-18959.
53. Nienaber JJ, Tachibana H, Naga Prasad SV, et al. Inhibition of receptor-localized PI3K preserves cardiac beta-adrenergic receptor function and ameliorates pressure overload heart failure. J Clin Invest. 2003;112:1067-1079. (Pubitemid 38056322)
54. Naga Prasad SV, Esposito G, Mao L, et al. Gbetagamma-dependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy. J Biol Chem. 2000;275:4693-4698. (Pubitemid 30108856)
55. Laporte SA, Oakley RH, Holt JA, et al. The interaction of betaarrestin with the AP-2 adaptor is required for the clustering of beta 2-adrenergic receptor into clathrin-coated pits. J Biol Chem. 2000;275:23120-23126. (Pubitemid 30646204)
56. Naga Prasad SV, Laporte SA, Chamberlain D, et al. Phosphoinositide 3-kinase regulates beta2-adrenergic receptor endocytosis by AP-2 recruitment to the receptor/beta-arrestin complex. J Cell Biol. 2002;158:563-575. (Pubitemid 34851714)
57. Naga Prasad SV, Jayatilleke A, Madamanchi A, Rockman HA. Protein kinase activity of phosphoinositide 3-kinase regulates betaadrenergic receptor endocytosis. Nat Cell Biol. 2005;7:785-796. (Pubitemid 41079051)
58. Perrino C, Naga Prasad SV, Mao L, et al. Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J Clin Invest. 2006;116:1547-1560.
59. Perrino C, Naga Prasad SV, Patel M, et al. Targeted inhibition of beta-adrenergic receptor kinase-1-associated phosphoinositide-3 kinase activity preserves beta-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrin overexpression. J Am Coll Cardiol. 2005;45:1862-1870. (Pubitemid 40779869)
60. Perrino C, Schroder JN, Lima B, et al. Dynamic regulation of phosphoinositide 3-kinase-gamma activity and beta-adrenergic receptor trafficking in end-stage human heart failure. Circulation. 2007;116:2571-2579.
61. Seropian IM, Abbate A, Toldo S, et al. Pharmacological inhibition of phosphoinositide 3-kinase gamma (PI3Kgamma) promotes infarct resorption and prevents adverse cardiac remodeling after myocardial infarction in mice. J Cardiovasc Pharmacol. 2010; 56(6):651-658.
62. Doukas J, Wrasidlo W, Noronha G, et al. Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction. Biochem Soc Trans. 2007;35:204-206. (Pubitemid 46596468)
63. Ban K, Cooper AJ, Samuel S, et al. Phosphatidylinositol 3-kinase gamma is a critical mediator of myocardial ischemic and adenosine-mediated preconditioning. Circ Res. 2008;103:643-653.
64. Siragusa M, Katare R, Meloni M, et al. Involvement of phosphoinositide 3-kinase gamma in angiogenesis and healing of experimental myocardial infarction in mice. Circ Res. 2010;106:757-768.